3-(Aminocarbonyl)-β-(3-cyclohexylpropyl)-N-hydroxy-1,2,4-oxadiazole-5-propanamide

3-(Aminocarbonyl)-β-(3-cyclohexylpropyl)-N-hydroxy-1,2,4-oxadiazole-5-propanamide Basic information
Product Name:3-(Aminocarbonyl)-β-(3-cyclohexylpropyl)-N-hydroxy-1,2,4-oxadiazole-5-propanamide
Synonyms:1,2,4-Oxadiazole-5-propanamide, 3-(aminocarbonyl)-β-(3-cyclohexylpropyl)-N-hydroxy-, (βR)-;(βR)-3-(Aminocarbonyl)-β-(3-cyclohexylpropyl)-N-hydroxy-1,2,4-oxadiazole-5-propanamide;UK 383367;5-[(1R)-4-Cyclohexyl-1-[2-(hydroxyamino)-2-oxoethyl]butyl]-1,2,4-oxadiazole-3-carboxamide;3-(Aminocarbonyl)-β-(3-cyclohexylpropyl)-N-hydroxy-1,2,4-oxadiazole-5-propanamide;CS-483;UK-383367 (UK 383367);3-(Aminocarbonyl)-beta-(3-cyclohexylpropyl)-N-hydroxy-1,2,4-oxadiazole-5-propanamide USP/EP/BP
CAS:348622-88-8
MF:C15H24N4O4
MW:324.38
EINECS:
Product Categories:Inhibitors
Mol File:348622-88-8.mol
3-(Aminocarbonyl)-β-(3-cyclohexylpropyl)-N-hydroxy-1,2,4-oxadiazole-5-propanamide Structure
3-(Aminocarbonyl)-β-(3-cyclohexylpropyl)-N-hydroxy-1,2,4-oxadiazole-5-propanamide Chemical Properties
Melting point 136-138℃
density 1.233
storage temp. Sealed in dry,Room Temperature
solubility DMSO: >30mg/mL
pka9.03±0.20(Predicted)
form powder
color white to off-white
optical activity[α]/D ≥15°, c = 0.5 in methanol
Safety Information
Hazard Codes Xn
Risk Statements 22
RIDADR UN 2811 6.1 / PGIII
WGK Germany 3
MSDS Information
3-(Aminocarbonyl)-β-(3-cyclohexylpropyl)-N-hydroxy-1,2,4-oxadiazole-5-propanamide Usage And Synthesis
UsesPotent and selective nonpeptidic inhibitor of procollagen C-proteinase (PCP) inhibitor. A potential dermal anti-scarring agent.
Biological Activityuk 383367 is a novel procollagen c-protein (pcp) inhibitor being investigated for the treatment of post-surgical dermal scarring, which potently inhibits the activity of pcp with the value of 50% inhibition concentration ic50 of 44 nm, as well as a selective inhibitor of matrix metalloproteinases (mmps) with values of ic50 >60,000 nm for mmp-2 and >10,000 nm for mmp-1, mmp-3, mmp-9 and mmp-4. although the mechanism is not clear yet, uk 383367 also exhibits weak inhibitory effects against phosphodiesterase-4 (pde-4) enzyme, including pde-4a, pde-4b, pde-4c and pde-4d, with values of ic50 of 1.8 μm, 1.5 μm, 2.4 μm and 0.9 μm respectively.g. a. allan, j. i. gedge, a. n. r. nedderman, s. j. roffey, h. f. small and r. webster. pharmacokinetics and metabolism of uk-383,367 in rats and dogs: a rationale for long-lived plasma radioactivity. xenobiotica 2006; 36(5): 399-418bailey s, fish pv, billotte s, bordner j, greiling d, james k, mcelroy a, mills je, reed c, webster r.ff. succinyl hydroxamates as potent and selective non-peptidic inhibitors of procollagen c-proteinase: design, synthesis, and evaluation as topically applied, dermal anti-scarring agents. bioorg med chem lett. 2008;18(24):6562-6567
storageStore at -20°C
3-(Aminocarbonyl)-β-(3-cyclohexylpropyl)-N-hydroxy-1,2,4-oxadiazole-5-propanamide Preparation Products And Raw materials
Tie2 kinase inhibitor Afatinib Ibrutinib PFI-1 Tubastatin-A Bosutinib

Email:[email protected] [email protected]
Copyright © 2024 Mywellwork.com All rights reserved.